Physician profile
Carl A Deirmengian
NPI 1205815503
$789,890.42
in general payments reported to CMS, 2019-2025
7 companies · $124K in 2025
The $124K reported for 2025 was more than what 97% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $109K · 2021: $102K · 2022: $106K · 2023: $109K · 2024: $110K · 2025: $124K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $328K · Education: $13K · Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $328,200.00 |
| Education | $13,000.00 |
| Food and Beverage | $1,633.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $789,467.96 | 2019-2025 | Iassist, Synovasure Alpha Defensin, Avitus Bone Harvester |
| Trice Medical, INC. | $271.49 | 2019 | |
| Ferring Pharmaceuticals INC. | $42.61 | 2025 | Euflexxa |
| Depuy Synthes Sales INC. | $39.07 | 2019-2022 | |
| Liberty Surgical INC. | $33.35 | 2020 | |
| Heraeus Medical, LLC. | $19.88 | 2023 | Palacos |
| Kci USA, INC. | $16.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,926.06 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Deirmengian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.